nVerses Capital’s Catalyst Pharmaceutical CPRX Stock Holding History

nVerses Capital’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2,500	Closed	-$49.7K	–	201
2024 Q3	$49.7K	Buy	+2,500	New	+$46.3K	0.02%	636

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

nVerses Capital's CPRX Position: Q4 2024 in Review

nVerses Capital sold out of Catalyst Pharmaceutical (CPRX) in Q4 2024, closing a stake of 2,500 shares — an estimated $49.7K sold.

nVerses Capital first reported a position in CPRX in Q3 2024 and held it in 1 quarter. The position peaked at $49.7K in Q3 2024. 336 funds tracked by Wall St. Rank hold CPRX as of Q4 2024.

nVerses Capital reported no remaining Catalyst Pharmaceutical position as of Q4 2024 after selling out during the quarter.
nVerses Capital sold 2,500 Catalyst Pharmaceutical shares in Q4 2024, an estimated $49.7K.
nVerses Capital first reported a position in Catalyst Pharmaceutical in Q3 2024 and held it in 1 quarter.
nVerses Capital's Catalyst Pharmaceutical position peaked at $49.7K in Q3 2024.
336 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2024.

Based on nVerses Capital's 13F filing for Q4 2024.